ALTHOUGH its use is anticipated
to be rare, a reversal agent has now
been developed to counter the
anticoagulant effect of Boehringer
Ingelheim’s Pradaxa (dabigatran).
Praxbind (idarucizumab) has
been approved by the Therapeutic
Goods Administration for use prior
to emergency surgery or urgent
procedures or in the event of life threatening
uncontrolled bleeding.
It’s action is described as effective
“within minutes” and treatment
with Pradaxa can be resumed
as early as 24 hours after the
administration of Praxbind, the
company has said.
Praxbind, not available on the
PBS, comes as a ready-to-use
solution with recommended dosing
of 5g, administered intravenously
as two consecutive infusions over
5-10 minutes, or as an injection.The above article was sent to subscribers in Pharmacy Daily's issue from 13 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 May 16
IN WESTERN Australia, Michael’s Chemist Group has started stocking therapeutic Nicotine Vaping Products (NVPs), pursuant to the Federal Government’s new vaping laws (PD 25 Mar).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.